Phathom's lead asset is vonoprazan, an oral small-molecule potassium competitive acid blocker that shows rapid, potent anti-secretory effects and has demonstrated clinical benefits in treating gastroesophageal reflux disease and H. pylori infection. The company's product aims to elevate stomach pH more effectively than PPI therapies, positioning itself for adoption among physicians serving an estimated 65 million patient market.
Cyborg Score Rationale
Phathom demonstrates strong commercial traction with $175M TTM revenue (as of Dec 2025) and over 790,000 VOQUEZNA prescriptions filled, reflecting successful market penetration. The company shows solid analyst support with a 'Strong Buy' consensus and 19.77% upside to price targets, though it remains unprofitable with operating losses.
Top Insights
2024 revenue reached $55.25 million, representing an 8001% increase from 2023, demonstrating explosive early commercial growth.
The company is advancing development programs across multiple acid-related GI disorders, including As Needed dosing for Non-Erosive GERD and Eosinophilic Esophagitis.
Analyst consensus rates the stock as 'Strong Buy' with a 12-month price target of $17.33, implying 19.77% upside potential.
The company completed a public offering in January 2026 of 6.875 million shares at $16.00 per share, raising capital for expansion initiatives.
Named Competitors
Proton Pump Inhibitors (PPIs) — Traditional acid-suppression therapy for GERD and related conditions